Complement and Podocytopathies: Do We Have a New Biomarker?

Complement and Podocytopathies: Do We Have a New Biomarker?

Saved in:

Bibliographic Details
Main Authors:	Miquel Blasco, Andrew S. Bomback
Format:	Article
Language:	English
Published:	Elsevier 2024-03-01
Series:	Kidney International Reports
Online Access:	http://www.sciencedirect.com/science/article/pii/S2468024924000482
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Diffuse Podocytopathy Associated With Semaglutide
by: Rose Mary Attieh, et al.
Published: (2024-05-01)

WCN24-802 ALPORT SYNDROME WITH PODOCYTOPATHY
by: NIHAL BASHIR, et al.
Published: (2024-04-01)

Non-invasive Diagnosis of Antinephrin–Associated Podocytopathy
by: Felicitas E. Hengel, et al.
Published: (2025-08-01)

The importance of detection of autoantibodies to podocytes in primary podocytopathies
by: Evgenia A. Kharionovskaya, et al.
Published: (2025-01-01)

Research status and recent advances of lupus podocytopathy
by: Yang Meng, et al.
Published: (2021-01-01)

Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy
by: Andrew S. Bomback, et al.
Published: (2025-01-01)

Do What We Have to Do
by: Yanín Arteaga Prado
Published: (2013-08-01)

WCN24-2512 LUPUS PODOCYTOPATHY: CASE REPORT
by: Alexandre Salvatore Pipino, et al.
Published: (2024-04-01)

Obinutuzumab in Rituximab-Resistant Podocytopathies: A Single-Center Experience
by: Andrea Angeletti, et al.
Published: (2025-08-01)

Graphs which have pancyclic complements
by: H. Joseph Straight
Published: (1978-01-01)

What’s new in medical renal pathology 2025: Updates on podocytopathy and immunofluorescence staining in medical kidney
by: Astrid Weins, et al.
Published: (2025-07-01)

Plants have two minds as we do
by: Tomonori Kawano, et al.
Published: (2025-12-01)

Autoantibodies Targeting Vinculin Reveal Novel Insight into the Mechanisms of Autoimmune Podocytopathies
by: Hanyan Meng, et al.
Published: (2025-01-01)

WCN24-2640 HISTOLOGICAL TRANSITION IN LUPUS PODOCYTOPATHY: REPORT OF TWO CASES
by: Alfredo Fonseca-Chavez, et al.
Published: (2024-04-01)

WCN24-1436 COLLAPSING LUPUS PODOCYTOPATHY, UNLIKE OTHER COLLAPSING GLOMERULOPATHIES?
by: Elisa Mendoza, et al.
Published: (2024-04-01)

WCN24-2478 PODOCYTOPATHY ASSOCIATED WITH IGA NEPHROPATHY: IS IT REALLY A PROGNOSTIC FACTOR?
by: BELENGALLEGOS VAZQUEZ, et al.
Published: (2024-04-01)

The differential expression of MAGI2 in glomerulopathies and its application as a molecular discriminator of podocytopathies
by: Florian Siegerist, et al.
Published: (2025-06-01)

PTH Assays: Understanding What We Have and Forecasting What We Will Have
by: Jose Gilberto H. Vieira
Published: (2012-01-01)

Plastic pollution: What have we done? What more can we do?
by: Haoxuan Yu, et al.
Published: (2024-11-01)

Psoriasis and Cardiovascular Risk—Do Promising New Biomarkers Have Clinical Impact?
by: Sirje Kaur, et al.
Published: (2017-01-01)

The normalizer problem for finite groups having normal $ 2 $-complements
by: Jidong Guo, et al.
Published: (2024-08-01)

Minimal Change Podocytopathy with Coexistent Thin Glomerular Basement Membrane following Exposure to Semaglutide
by: Karthik Kovvuru, et al.
Published: (2025-01-01)

Orthobiologics in Foot and Ankle: Do We Have Enough Evidence?
by: Sandeep Patel, et al.
Published: (2024-09-01)

DO WE REALLY HAVE ARCHAEOLOGICAL EVIDENCE FOR JEWISH GLADIATORS?
by: Haggai Olshanetsky
Published: (2021-10-01)

Healthcare resilience in the climate crisis: Do we have any?
by: Rosa Montero, et al.
Published: (2025-03-01)

Echocardiography in acute pulmonary embolism – what do we have?
by: I. Bayraktarova
Published: (2024-12-01)

Chernobyl and Fukushima nuclear accidents: What have we learned and what have we done?
by: Đurović Branka, et al.
Published: (2016-01-01)

WCN24-1435 LUPUS PODOCYTOPATHY: CASE SERIES OF 4 CASES FROM DOMINICAN REPUBLIC
by: Eliana Dina-Batlle, et al.
Published: (2024-04-01)

WCN25-1613 GLUCOCORTICOID TOXICITY INDEX IN MEMBRANOUS NEPHROPATHY AND PODOCYTOPATHIES IN ADULT: A PILOT STUDY
by: RAJESH KUMAR, et al.
Published: (2025-02-01)

WCN25-3992 EFFACED BUT NOT ERASED - A CASE OF CONSECUTIVE RELAPSES OF LUPUS PODOCYTOPATHY IN RENAL TRANSPLANTS
by: Renuka Tolani, et al.
Published: (2025-02-01)

COVID Diagnostics: Do We Have Sufficient Armamentarium for the Present and the Unforeseen?
by: Bineeta Kashyap, et al.
Published: (2020-07-01)

Asthma treatable traits: How far do we have to go?
by: Honglei Shi, et al.
Published: (2025-04-01)

Humoral complementomics – exploration of noninvasive complement biomarkers as predictors of renal cancer progression
by: Margot Revel, et al.
Published: (2024-12-01)

ASICs in PET: what we have and what we need
by: Vanessa Nadig, et al.
Published: (2025-02-01)

WCN24-420 SAFETY AND EFFICACY OF ANIFROLUMAB IN IMMUNE COMPLEX AND APOL-1 ASSOCIATED LUPUS PODOCYTOPATHY
by: James Tumlin, et al.
Published: (2024-04-01)

Markers of inflammation, fibrosis, endothelial dysfunction, and podocytopathy in patients with long-term type 1 diabetes mellitus
by: M. I. Yevloyeva, et al.
Published: (2025-05-01)

Interactivity in a Distance Learning Environment What is it? How do we know we have it? What’s the Value Added?
by: Collen Sexton
Published: (2014-05-01)

THE REVOLUTION, WE HAVE ALMOST OVERSLEPT
by: D. A. Zateyshchikov, et al.
Published: (2015-10-01)

Complement C3c as a Biomarker in Heart Failure
by: A. Frey, et al.
Published: (2013-01-01)

Psychological fitness for work: do we still have a long way to go?
by: Giuseppe Ferrari
Published: (2016-07-01)